

# Hui Shao

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4353423/hui-shao-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43  
papers

307  
citations

11  
h-index

16  
g-index

48  
ext. papers

486  
ext. citations

5.5  
avg, IF

3.8  
L-index

#	Paper	IF	Citations
43	Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO). <i>Pharmacoeconomics</i> , <b>2018</b> , 36, 1125-1134	4.4	37
42	Is hypoglycemia fear independently associated with health-related quality of life?. <i>Health and Quality of Life Outcomes</i> , <b>2014</b> , 12, 167	3	36
41	Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices: An Updated Review. <i>Pharmacoeconomics</i> , <b>2018</b> , 36, 17-27	4.4	29
40	Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , <b>2017</b> , 33, 359-369	2.5	24
39	Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. <i>Pharmacoeconomics</i> , <b>2019</b> , 37, 777-818	4.4	16
38	Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge. <i>Value in Health</i> , <b>2020</b> , 23, 1163-1170	3.3	16
37	Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation. <i>Pharmacoeconomics</i> , <b>2019</b> , 37, 921-929	4.4	15
36	Serum uric acid as a risk factor of all-cause mortality and cardiovascular events among type 2 diabetes population: Meta-analysis of correlational evidence. <i>Journal of Diabetes and Its Complications</i> , <b>2019</b> , 33, 107409	3.2	13
35	Long-term outcomes associated with triple-goal achievement in patients with type 2 diabetes mellitus (T2DM). <i>Diabetes Research and Clinical Practice</i> , <b>2018</b> , 140, 45-54	7.4	11
34	Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005-2007 and 2015-2017. <i>Diabetes Care</i> , <b>2020</b> , 43, 2396-2402	14.6	11
33	Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies. <i>Journal of Medical Economics</i> , <b>2015</b> , 18, 974-89	2.4	10
32	Cost Sharing of Disease-Modifying Treatments (DMTs) as Policy Lever to Improve DMTs Access in Multiple Sclerosis. <i>Value in Health</i> , <b>2018</b> , 21, 1083-1089	3.3	10
31	The impact of a bundled policy intervention on improving the performance of rural healthcare in China. <i>International Journal for Equity in Health</i> , <b>2016</b> , 15, 46	4.6	7
30	A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes. <i>Current Diabetes Reports</i> , <b>2020</b> , 20, 12	5.6	6
29	Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model. <i>Value in Health</i> , <b>2019</b> , 22, 1402-1409	3.3	6
28	Estimating benefit equity of government health subsidy in healthcare Services in Shandong Province, China: a cross-sectional study. <i>International Journal for Equity in Health</i> , <b>2018</b> , 17, 61	4.6	5
27	Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis. <i>BMC Medicine</i> , <b>2020</b> , 18, 378	11.4	5

26	Association between frailty and life satisfaction among older people in Shandong, China: the differences in age and general self-efficacy. <i>Psychogeriatrics</i> , <b>2020</b> , 20, 172-179	1.8	4
25	An exploratory spatial analysis of overweight and obesity among children and adolescents in Shandong, China. <i>BMJ Open</i> , <b>2019</b> , 9, e028152	3	4
24	Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium-Glucose Transporter 2 Inhibitors. <i>Diabetes Care</i> , <b>2020</b> , 43, 1530-1536	14.6	3
23	Influence of Diabetes Complications on HbA Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis. <i>Diabetes Care</i> , <b>2019</b> , 42, 2136-2142	14.6	3
22	Trajectories of Short Physical Performance Battery Are Strongly Associated with Future Major Mobility Disability: Results from the LIFE Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	3
21	Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study. <i>Diabetes Care</i> , <b>2020</b> , 43, 2847-2852	14.6	3
20	Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018. <i>Diabetes Care</i> , <b>2021</b> , 44, 925-934	14.6	3
19	Estimating costs of diabetes complications in people . <i>Journal of Diabetes and Its Complications</i> , <b>2020</b> , 34, 107735	3.2	2
18	Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 35, 107972	3.2	2
17	Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e227705	10.4	2
16	Mapping and Analyzing Stakeholders in China's Essential Drug System by Using a Circular Model: Who We Should Deal with Next?. <i>Value in Health Regional Issues</i> , <b>2015</b> , 6, 111-117	1.6	1
15	Does the Encounter Type Matter When Defining Diabetes Complications in Electronic Health Records?. <i>Medical Care</i> , <b>2020</b> , 58 Suppl 6 Suppl 1, S53-S59	3.1	1
14	Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> 2019;42:2298-2306. <i>Diabetes Care</i> , <b>2020</b> , 43, e25	14.6	1
13	Projecting Long-Term Diabetes Complications through a BRAVO-Based Mock Simulation for Promoting Diabetes Prevention Program (DPP). <i>Diabetes</i> , <b>2018</b> , 67, 701-P	0.9	1
12	9-OR: Cost Effectiveness of the New 2018 ACP Glycemic Control Guideline among U.S. Adults with Type 2 Diabetes. <i>Diabetes</i> , <b>2019</b> , 68, 9-OR	0.9	1
11	Estimates of insulin needs and dispensation given wastage, alternative glycemic targets, and non-insulin therapies in US populations with type 2 diabetes mellitus: A microsimulation study. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 35, 107839	3.2	1
10	Income, Relative Deprivation and the Self-Rated Health of Older People in Urban and Rural China. <i>Frontiers in Public Health</i> , <b>2021</b> , 9, 658649	6	1
9	Trends in Total and Out-of-pocket Payments for Insulin Among Privately Insured U.S. Adults With Diabetes From 2005 to 2018. <i>Diabetes Care</i> , <b>2021</b> ,	14.6	1

8	Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes.. <i>Diabetes Care</i> , <b>2022</b> , 45, e32-e33	14.6	○
7	Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study.. <i>Journal of Diabetes and Its Complications</i> , <b>2022</b> , 108132	3.2	○
6	Comparing the downstream costs and healthcare utilization associated with the use of low-dose computed tomography (LDCT) in lung cancer screening in patients with and without alzheimer's disease and related dementias (ADRD). <i>Current Medical Research and Opinion</i> , <b>2021</b> , 37, 1731-1737	2.5	○
5	Selecting a target population for type 2 diabetes lifestyle prevention programs: A cost-effectiveness perspective.. <i>Diabetic Medicine</i> , <b>2022</b> , e14847	3.5	○
4	Newer glucose-lowering drugs and risk of dementia: A meta-analysis of cardiovascular outcome trials. <i>Journal of the American Geriatrics Society</i> ,	5.6	○
3	Cost-Effectiveness of the New 2018 American College of Physicians Glycemic Control Guidance Statements Among US Adults With Type 2 Diabetes. <i>Value in Health</i> , <b>2021</b> , 24, 227-235	3.3	
2	A varied approach to left ventricular assist device follow-up improves cost-effectiveness. <i>Current Medical Research and Opinion</i> , <b>2021</b> , 37, 1501-1505	2.5	
1	The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010-2018. <i>Current Medical Research and Opinion</i> , <b>2021</b> , 37, 1875-1880	2.5	